Health Care Stocks Warning: VERO RSI at 95.9 Indicates Overbought
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy IBRX?
Source: Benzinga
- Surge in VERO Stock: Venus Concept Inc (NASDAQ:VERO) saw its stock price soar by 426% over the past five days, closing at $7.89 with an RSI of 95.9, indicating a significant overbought condition that investors should approach with caution.
- Increased Investor Holdings: Madryn Asset Management disclosed a 91% stake in VERO in an SEC filing, signaling a strong investment intent that may influence market confidence in the stock.
- Strong Performance of IBRX: ImmunityBio Inc (NASDAQ:IBRX) has surged over 100% year-to-date and gained 136% in the past five days, closing at $5.52 with an RSI of 95.4, reflecting robust market momentum.
- Clinical Trial Success: ImmunityBio exceeded internal enrollment expectations in its randomized registrational trial for BCG-naïve non-muscle-invasive bladder cancer, further boosting market confidence in its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
ANKTIVA Approved for Commercial Use in Saudi Arabia
- Approval Milestone: ANKTIVA (nogapendekin alfa inbakicept) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking a significant strategic expansion for the company in the Middle East market.
- Patient Identification: Initial patients have been identified for ANKTIVA treatment, which not only addresses the urgent need for new cancer therapies in Saudi Arabia but also has the potential to enhance ImmunityBio's market share in the region.
- Partnership Distribution: ANKTIVA is being distributed through partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, ensuring rapid market entry for the product.
- Growing Market Demand: The rapidly increasing cancer burden in the MENA region, particularly the rising incidence of lung and bladder cancers, underscores the urgent need for innovative treatment options, making ANKTIVA's launch timely and critical for patient care.
See More
U.S. Stock Futures Rise Amid Iran Peace Talks and Leadership Changes
- U.S. Stock Futures Rise: Early Tuesday, U.S. stock futures saw a modest increase, with S&P 500 and Nasdaq futures up 0.1% and Dow futures up 0.3%, indicating a potential stabilization in investor sentiment following recent volatility in tech-heavy indices.
- Iran Peace Talks: Reports suggest that Iran may engage in peace talks with the U.S. ahead of a looming ceasefire deadline, although internal resistance from the Revolutionary Guard could complicate these discussions, impacting geopolitical stability in the region.
- Apple Leadership Change: Tim Cook announced his resignation as CEO of Apple, with John Ternus, the current SVP of Hardware Engineering, taking over during a critical period of AI integration, which may influence investor confidence in the company's future direction.
- JPMorgan Raises Year-End Target: JPMorgan has raised its S&P 500 year-end target to 7,600, reflecting a bullish outlook on the market, while traders are also bracing for the upcoming March retail sales data, which could significantly affect market trends.
See More
ImmunityBio Faces Class Action for Misleading Investors
- Class Action Notice: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 25, 2026, aimed at protecting investor rights and seeking compensation.
- FDA Warning Letter Exposed: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the lead product ANKTIVA, with a March 24, 2026 FDA warning letter indicating misleading claims that ANKTIVA could cure and prevent all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's common stock fell by 21%, losing $1.98 per share to close at $7.42 on March 24, 2026, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit documents by May 26, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members eligible for recovery.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, focusing on the accuracy and completeness of information disclosed to investors.
- Lawsuit Background: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives misrepresented Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah indicated that investors who suffered losses exceeding $100,000 in ImmunityBio securities are encouraged to contact them to learn about eligibility for participation, highlighting potential legal liabilities and a decline in investor confidence.
- Reputational Risk: This investigation could negatively impact ImmunityBio's market performance, particularly as the company faces legal challenges, potentially leading to diminished investor confidence in its future business outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a securities fraud class action lawsuit for material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has shaken investor confidence.
- Stock Price Drop: Following an FDA warning on March 24, 2026, regarding misleading claims about Anktiva, ImmunityBio's stock plummeted by 21.12%, closing at $7.42 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are urged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, indicating a crisis of trust in the company's management.
- Legal Support: Kessler Topaz Meltzer & Check, LLP is offering free consultations and encouraging investors to reach out for more information on how to participate in the lawsuit, demonstrating a commitment to protecting investor rights.
See More
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
ANKTIVA Approved for Commercial Use in Saudi Arabia
- Approval Milestone: ANKTIVA (nogapendekin alfa inbakicept) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking a significant strategic expansion for the company in the Middle East market.
- Patient Identification: Initial patients have been identified for ANKTIVA treatment, which not only addresses the urgent need for new cancer therapies in Saudi Arabia but also has the potential to enhance ImmunityBio's market share in the region.
- Partnership Distribution: ANKTIVA is being distributed through partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, ensuring rapid market entry for the product.
- Growing Market Demand: The rapidly increasing cancer burden in the MENA region, particularly the rising incidence of lung and bladder cancers, underscores the urgent need for innovative treatment options, making ANKTIVA's launch timely and critical for patient care.
See More
U.S. Stock Futures Rise Amid Iran Peace Talks and Leadership Changes
- U.S. Stock Futures Rise: Early Tuesday, U.S. stock futures saw a modest increase, with S&P 500 and Nasdaq futures up 0.1% and Dow futures up 0.3%, indicating a potential stabilization in investor sentiment following recent volatility in tech-heavy indices.
- Iran Peace Talks: Reports suggest that Iran may engage in peace talks with the U.S. ahead of a looming ceasefire deadline, although internal resistance from the Revolutionary Guard could complicate these discussions, impacting geopolitical stability in the region.
- Apple Leadership Change: Tim Cook announced his resignation as CEO of Apple, with John Ternus, the current SVP of Hardware Engineering, taking over during a critical period of AI integration, which may influence investor confidence in the company's future direction.
- JPMorgan Raises Year-End Target: JPMorgan has raised its S&P 500 year-end target to 7,600, reflecting a bullish outlook on the market, while traders are also bracing for the upcoming March retail sales data, which could significantly affect market trends.
See More
ImmunityBio Faces Class Action for Misleading Investors
- Class Action Notice: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 25, 2026, aimed at protecting investor rights and seeking compensation.
- FDA Warning Letter Exposed: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the lead product ANKTIVA, with a March 24, 2026 FDA warning letter indicating misleading claims that ANKTIVA could cure and prevent all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's common stock fell by 21%, losing $1.98 per share to close at $7.42 on March 24, 2026, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit documents by May 26, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members eligible for recovery.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, focusing on the accuracy and completeness of information disclosed to investors.
- Lawsuit Background: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives misrepresented Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah indicated that investors who suffered losses exceeding $100,000 in ImmunityBio securities are encouraged to contact them to learn about eligibility for participation, highlighting potential legal liabilities and a decline in investor confidence.
- Reputational Risk: This investigation could negatively impact ImmunityBio's market performance, particularly as the company faces legal challenges, potentially leading to diminished investor confidence in its future business outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a securities fraud class action lawsuit for material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has shaken investor confidence.
- Stock Price Drop: Following an FDA warning on March 24, 2026, regarding misleading claims about Anktiva, ImmunityBio's stock plummeted by 21.12%, closing at $7.42 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are urged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, indicating a crisis of trust in the company's management.
- Legal Support: Kessler Topaz Meltzer & Check, LLP is offering free consultations and encouraging investors to reach out for more information on how to participate in the lawsuit, demonstrating a commitment to protecting investor rights.
See More
